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1. Introduction 
On August 6 and 9, 1945, nearly 65 years ago, atomic bombs (ABs) were dropped on two 
Japanese cities, Hiroshima and Nagasaki. The explosive powers of these two bombs are said 
to be equal about 12.5 kilotons of TNT for Hiroshima bomb and 22 kilotons for Nagasaki 
bomb. The dissipation of energy is believed to have been in the ratios consisting of 50% of 
bomb blast, 35% of thermal rays and 15% of radiation. Heat and bomb blast caused death in 
AB survivors within two weeks after bombing. On the other hand cause of death after two 
weeks were closely related to radiation. The initial radiation caused by the Hiroshima bomb 
composed mostly gamma rays including about 10 % of neutrons, on the while Nagasaki 
bomb emitted only gamma rays, In the both cities, a 50% death rate was estimated for those 
who were exposed at 1.2 km on the hypocenter. LD50 value in human was estimated as 
around 4 Gy from Hiroshima AB victims. Bone marrow depletion by radiation was the most 
critical damage leading to death. There victims who died early had extensive bone marrow 
damage, manifested by leukopenia and thrombocytopenia. Epilation began one to four 
weeks post-exposure.  
Epidemiological studies have established that leukemia develops more frequently among 
atomic bomb (AB) survivors than in the general populations(Pierce et al.1996). Observed 
cancers and the approximate dates at which significant increases became evident were 
leukemia in 1950, thyroid 1955, breast and lung cancer in 1965, and gastric and colon cancer in 
1975, and multiple myeloma in 1975. The incidence of leukemia peaked 8-10 years after the 
bombing, and a higher incidence was found in survivors exposed to higher radiation doses 
and those exposed at a younger age. The incidences of chronic myelocytic leukemia (CML) 
and acute lymphocytic leukemia(ALL) were decreased to the control level after 15-20 years 
and 25-30 years after the bombing, respectively, while the relative risk of AML development is 
still increased in persons who were exposed to the bombing at the age of 20-39 years炷Preston 
et al.1994). The peak leukemia prevalence among Hiroshima survivors has passed, but even in 
recent years the death rate from leukemia among proximately exposed survivors remains 
higher than the mean death rate of the non-exposed and for all Japan. Among those exposed 
within 2 km of the hypocenter of Hiroshima, there was a marked increase in CML and the 
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ratio of acute type to chronic type was 1.6, whereas almost the same ratio as the all-Japan ratio 
of 3.8 was observed in those exposed beyond 2 km (Kamada and Tanaka 1983). The Leukemia 
Registry Study has revealed that the younger the individual at the time of bombing , the 
greater was the risk of leukemia during the early period and the more rapid was decline 
thereafter. On the other hand, in the group aged 45 or more at the time on bombing, the 
increase in risk occurred later and persisted during the period 1960-1975. Acute type 
leukemia contributed to these trends. More recent reports have indicated that the incidences 
of acute myelocytic leukemia (AML) and MDS were still high even 40-60 years after the 
bombing (Richardson et al., 2009; Iwanaga et al., 2011). These results suggest that mechanism 
for development of radiation-induced AML seems to be different those of ALL and CML. 
In summary, AB-related leukemia and solid tumor exhibit the following characteristics: (1) 
Leukemia and cancer risk increased with dose. (2) The leukemia risk increased with 
decreasing age at the time of bombing. (3) Unlike leukemia, the latency period increase with 
decreasing age at the time bombing, with a marked radiation effect evident when survivors 
reached the age level at which the cancers frequently occur. AB-survivors population is very 
unique and can be used for clarifying the mechanisms responsible for radiation-induced 
leukemia. 
2. Dosimetry system of AB radiation 
The former T65D system of dosimtry had been used as the most accurate method of 
estimating the doses received by individual survivors although this has now been replaced 
by the DS86 and DS01 system. Original T65D system was based on the nuclear testing 
conducting at Nevada, USA, and was devised in 1965 as a formula that incorporated various 
parameters such as distance from the hypocenter, and transmission factors for shielding 
materials, etc. AB survivors are defined as those directly exposed in the city at the time of 
the bombing within 5 km of the hypocenter. In order to permit more detail calculations, the 
DS86 and DS01 system was formulated in 1986 and 2001 based on elementary physical 
processes, and enabled computer analysis of the different processes involved from the time 
of emission until arrival at various human organs, including factors of calculations of 
weather and soil. Dose of gamma rays was increased four times, on the other hand, neuron 
dose is decreased more than 10% of former values. The DS86 system was used for present 
study. The DS86 assessment of Hiroshima AB radiation contained low energy neutrons of 
less than 1.0 MeV. If the hypothesis that the RBE of low energy neutrons is higher than that 
of fission neutrons with 2.3 MeV is true, Hiroshima AB radiation would have created a 
significantly higher degree of biological effects. Therefore our experiments using 252Cf-
neutrons and monochromatic neutrons was performed in Hiroshima University, The 
relative biological effectiveness (RBE) of dicentric chromosomes aberrations was increased 
to 10.7 at 0.75 MeV from 3.9 at 252Cf- neutrons and reached to 16.4 as highest RBE value at 
0.37 MeV, but the value was decreased to 11.2 at 0.186 MeV (Tanaka et al. 1994, 1999). RBE of 
low energy neutron is higher than that of fission neutrons. It is still now in question how 
radiation containing low energy neutron effects on developments of leukemia and cancer. 
3. Chromosome aberrations in AB-related leukemia 
We have investigated chromosome aberrations in leukemias developing individuals with a 
history of heavily exposure to AB radiation(Kamada et al.,1991, Nakanishi et al., 1999) and 
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have reported cytogenetic and molecular biological alterations in AB-related leukemias 
(Kamada and Tanaka 1983; Tanaka et al., 1989; Tanaka et al., 1991; Kamada et al., 1991). In the 
present study, to clarify the mechanisms responsible for radiation-induced leukemia, we 
analyzed cytogenetic and molecular biological alterations in AB-related leukemias in 
comparison with those in de novo (non-AB-related) leukemia. Acute lymphocytic leukemia 
(ALL), chronic myeloid leukemia (CML) and other hematological disorders were excluded 
from the present analysis. In our previous cytogenetic molecular biological studies of 132 
patients with AB-related leukemia observed during 1978-1999, 33 patients with acute 
myeloid leukemia (AML) had been exposed to DS86 doses of exceeding 1Gy. Eight more AB 
patients were included in the present study, after our previous publication in 1999 
(Nakanishi et al., 1999). This revealed that among 132 patients with AB-related leukemias 
observed during 1978-1999, 33 patients with AML had been exposed to doses of more than 1 
Gy on the basis of the Dose System 1986 (DS86). Leukemia patients were divided into three 
groups according to their exposure status; those who received more than 1 Gy bone marrow 
dose, 0.01-0.99 Gy and non-exposed groups (Table 1). Chromosome aberrations in the 33 
patients were compared with those in 588 control patients with de novo AML who had been 
born before August 1945. Thirty-two and 58 AB-related patients who had been exposed to 
0.01-0.99 Gy and less than 0.01Gy were also analyzed for chromosome aberrations using the 
same methods. 
Bone marrow cells or peripheral lymphocytes from 33, 32, 58 and 588 leukemia patients with 
and without AB radiation exposure, respectively, were cultured for 24 h and harvested for 
chromosome preparations. These preparations were stained by the Giemsa banding 
procedure and karyotyped according to ISCN (2009). Mean numbers of aberrant 
chromosomes were scored in karyotypes of the main leukemia clone in each patient. One 
thousand metaphases were observed by microscopy, and spontaneous chromosome 
aberrations such as chromatid breaks, gaps, and hyperploid cells, which are useful markers 
of radiation-induced chromosome instability, were also detected. FISH analyses were 
performed using cosmid and YAC probes such as MLL and CD3 on 11q22-23 regions of 
chromosome 11 for mapping of chromosome breakpoints in each patient. 
The leukemia subtypes of FAB classification in the patients in each group were analyzed. 
Among 33 AB-related patients exposed more than 1Gy, 13 had been diagnosed as having 
MDS (RA or RAEB) by the FAB classification before the development of AML. The others 
had been diagnosed as having AML (AMLM1- 8 patients; AMLM2- 8 patients; AMLM4- 1 
patient; AMLM5- 1 patient; AMLM6- 1 patient). None of the patient had AML M3.  
Chromosome complexity was indicated by the number of aberrant chromosomes found in 
the main leukemic clone. Of the 33 AB-related patients who had been exposed to > 1Gy, 
only one (3.1%) had a normal karyotype, compared with 45.7% of AB-related patients 
exposed to 0.01-0.99 Gy, and 62.5% exposed to < 0.01 Gy. On the other hand, 44.1% of the 
non-exposed control leukemia patients (246 out of 558) had a normal karyotype. The 
numbers of aberrant chromosome per metaphase were 3.69, 1.89, 2.0 and 0.93 in AB-related 
leukemia patients who had been exposed to>1Gy, 0.01-0.99 Gy, <0.01Gy and non-exposed, 
respectively. These results indicate that AB-related patients who had been exposed >1.0 Gy 
had more complex chromosome aberrations in their leukemic cells. Both-AB-leukemia 
groups with exposure to 0.01-0.99 Gy and <0.01 Gy also had higher numbers of aberrant 
chromosomes per cell. Only 3.1% of patients with AB-leukemia who had been exposed to > 
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1 Gy had normal karyotype, while 45.7% and 62.5% of those exposed to 0.01-0.99 Gy and 
<0.01 Gy did so. About half of the AML patients showed normal karyotype. 
Specific chromosome aberrations that were found at high frequencies are also listed in Table 
1. Deletion of chromosome 20[del(20)] and loss of chromosome 20 were found in 10 patients, 
and der(11)or del(11) at 11q13-11q22 of chromosome 11 in 10 patients. On the other hand, 
non-exposed patients had a higher number of t(8;21) and t(15;17) translocations, which is 
specific to AML FAB type M2 and M3,respectively. The groups exposed to 0.01-0.99 Gy and 
<0.01Gy had no representative chromosome aberrations and lower percentages of t(8;21) 
and t(15;17) than the patient with de novo AMLs. 
 
DS86 dose (Gy) Number 
of  patients 
Percentage 
with a 
normal 
karyotype 
Number 
of aberrant 
chromosomes per
metaphase 
Specific 
chromosome 
aberrations 
AB patients 
exposed to 
>1.0Gy 
33 3.1% 3.69 
del(20)(q11) 
der(11)(q23) 
der(11)(q13) 
0.01-0.99Gy 32 45.7% 1.89 - 
<0.01Gy 58 62.5% 2.0 - 
Non-exposed 
patients 558 44.1% 0.93 
t(8;21) 
t(15;17) 
Table 1. Comparison of chromosome aberrations found in patients with AB leukemia and 
patients with de novo leukemia 
The incidences of several leukemia-specific chromosome aberrations were compared 
between the 33 patients with AB-related leukemia who were exposed to >1 Gy or non-
exposed, and the 558 patients with de novo leukemias (Fig.1). Deletion of chromosome 5 or 
loss of chromosome [del(5)/-5] showed the highest incidence, but the incidences did not 
differ between the two groups. Deletion of chromosome 7 or monosomy of chromosome 
7[del(7)/-7] showed the second highest incidence, and these aberrations were found more 
frequently in de novo leukemias. Deletion (20)/-20 and deletion and derivative of 
chromosome 11 at 11q13-11q22 were observed in higher frequencies in patients with AB-
related leukemia. Deletion or monosomy of chromosome 13 [del(13)/-13] was also more 
frequent in AB-related leukemias [2 of 33 in del(13) and 3 of 33 in monosomy 13]. 
Translocations of t(8;21), t(15;17), inv(16) and t(9;22) were detected only in de novo 
leukemias. Further FISH analysis using target gene probes were performed, and the results 
indicated that the breakpoints associated with derivative translocations at 11q22-23 of 
chromosome 11 [der(11)t(11;┙)(q22-23;┙)]lay outside the MLL gene. FISH analysis using 
whole chromosome painting of chromosome 8 and target gene probes demonstrated severe 
complex chromosome aberrations containing chromosome segmental jumping 
translocations(SJT) at 8q24 of chromosome 8 and 11q22-23 of chromosome 11 (Tanaka et al, 
2001). MYC oncogene signals located on some regions on the long arm of chromosome 8 and 
several other chromosomes, which were considered to translocate to several other 
chromosomes from original region on chromosome 8 (8q24). The phenomenon is known as 
segmental jumping chromosomal translocation(SJT) (Tanaka et al., 1997). In conclusion, AB- 
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Fig. 1. Comparison of frequencies of each type of chromosome aberration between AB-
related leukemias and de novo leukemias 
related leukemia patients showed more complex chromosome aberrations and did not have 
any leukemia-specific chromosome aberrations such as t(8:21) and t(9;22). 
4. Oncogene alterations in leukemias developed from atomic bomb survivors 
Alterations in the AML1 and MLL oncogenes in AML patients were also analyzed by PCR-
SSCP and FISH, respectively, and compared with those in the de novo in AMLs. Stored 
DNAs were available from 9 patients with AB-related leukemia, including 6 patients who 
had been exposed > 1.0 Gy. These leukemia DNAs were analyzed for AML1 oncogene 
alterations by PCR-SSCP. Exons 1 and 3 in the AML1 gene, which overlaps the RUNT 
domain of the AML1 gene were analyzed. 
Runt domain contains exons 3, 4 5, 6 and 7. PCR-SSCP and DNA sequence analyses of the 
AML1 gene on human chromosome 21 were performed in 8 AML patients who had been 
heavily exposed to the AB radiation. Genomic DNAs were amplified by PCR in a total 
volume of 20 µl containing PCR buffer. PCR of exons 1 and 3 of the AML1 gene was 
performed using forward/reverse primers for the flanking intron. To identify AML1 gene 
mutations, PCR-SSCP analysis was performed on a Gene Phor system (Amersham 
Pharmacia Biotech). After gelelectrophoresis, the gels were silver-stained to visualize the 
bands. All PCR products with abnormal bands detected by PCR-SSCP were confirmed by 
independent amplification and PCR-SSCP analysis. For identification of AML1 gene 
mutations, PCR products that showed abnormal bands were subcloned into a pCR2.2 vector 
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(Invitrogen), and 10 independent clones were sequenced in both directions using a BigDye 
Terminator Cycle sequencing kit (Perkin-Elmer) and analyzed on an ABI Prism 310 Genetic 
Analyzer (Perkin Elmer). To confirm mutations, PCR products from the cDNA were also 
sequenced. First-strand cDNA was synthesized using total RNA and random hexamers with 
SuperScriptsII reverse transcriptase (Gibco). The cDNA products were amplified with the 
primers and subcloned PCR products were sequenced as described above. PCR of exon 3 of 
the AML1 gene performed using the following flanking intronic , forward/reverse primers; 
5’-AGCTGTTTGCAGGGTCCTAA-3’/ 5’-GTCCTCCCACCACCCTCT-3’. The cDNA 
products were amplified with the following primers; 5’-GCAGGGTCCTAACTCAATCG-3’/ 
5’-GCTCGGAAAAGGACAAGCTC-3’, and subcloned PCR products were sequenced as 
described above. 
Two patients had gene rearrangement in exon3 of AML1. These samples were used for 
subsequent DNA sequence analysis and showed C to A, G to A and G to T mutations, 
respectively. When we further analyzed exon 1 of AML1, another three patients who had 
been exposed to >1.0 Gy were found to have an abnormal band in PCR-SSCP analysis. Exon 
1 is located outside the RUNT domain of the AML1 gene. These might be heteromorphic 
abnormality because they had the same G to T transition. Two of 6 patients with AB-related 
AML had abnormality in exon 3 of AML1.  
The MLL gene on the long arm of chromosome 11 was analyzed in 3 patients by the 
Southern blot method. All of the 6 patients with AB-related AML were shown to have the 
chromosome breakpoint at 11q22-23 and 11q25, lying outside the MLL gene by FISH 
analysis using several region-specific cosmid probes. Two of the 6 patients had been 
exposed to >1 Gy. The karyotypes in the 6 patient showed r(11), der(11)(q22), del(11)(q23) 
and inv(11)(p15q21) in one patient each and add(11)(q21) in 2 patients. 
5. Incidence of micronucleus (MN)in lymphocytes and bone marrow cells 
from healthy AB survivors 
It has not yet been clarified whether chromosomal instability is preserved in lymphocytes 
and bone marrow cells from healthy AB survivors. Chromatid-type aberrations and MN are 
suitable markers for chromosomal instability because they appear several days after 
exposure.  Both of bone marrow and lymphocytes samples from these AB-survivors were 
obtained after 40-50 years after AB radiation exposure. Micronucleus (MN) was evident 
incidences in the lymphocytes and bone marrow erythroblasts in healthy AB survivors. 
Furthermore, MN in bone marrow erythrocytes or lymphocytes in 35 and 20 healthy AB 
survivors without leukemia or hematological disease, respectively, were analyzed using 
stored smear slides. Cytochalasin B (0.5 µg/ml) was not used for the present lymphocyte 
MN assay. MN was observed in 1,000 PHA-stimulated lymphocytes, and in 500 bone 
marrow erythroblasts on smear slides. Cells with MN were scored by microscopy. Exposure 
doses in most of the healthy AB survivors and patients with AB-related leukemia had been 
estimated by DS86 dosimetry. Individual approximate exposure doses in the remaining AB 
survivors were estimated on the basis of the chromosome aberration rate in peripheral 
blood.  
Thirty five AB survivors who had been exposed 2km from the hypocenter in Hiroshima city 
and whom exposure doses (DS86)had been estimated, were used for MN analysis of bone 
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marrow erythroblasts. Bone marrow smear slide was stained with May-Grünwald Giemsa 
solution were used for this purpose. Eleven age-matched controls were also studied for 
comparison. Frequencies of MN in bone marrow erythroblasts were increased by exposure 
to doses up to 3Gy and after the dose they were slightly decreased. Twenty healthy AB 
survivors for whom exposure doses had been estimated were used for lymphocyte 
chromosomal instability. The incidences of MN in 1,000 lymphocytes on peripheral blood 
smears stained with May-Grünwald Giemsa solution from these AB-survivors were 
observed in the present analysis. The age-matched non-exposed controls had 1-8 MN per 
1,000 lymphocytes, whereas AB-survivors who had been exposed to up to 3 Gy showed a 
dose-dependent increase of MN in lymphocytes, although small errors in measurement 
could have occurred in the absence of addition of cytochalacin B. The AB-survivors who had 
been exposed to more than 4-5 Gy had a slightly lower number of MN than those who had 
been exposed to 3 Gy. The incidence of MN in lymphocytes clearly increased in a dose-
dependent manner. Healthy AB survivors had a higher incidence of MN in lymphocytes 
and bone marrow erythroblasts, depending on their DS86 exposure dose. These results 
indicate the presence of AB radiation-induced chromosome instabilities in both bone 
marrow erythroblasts and lymphocytes of healthy AB survivors. 
A healthy AB survivor who developed colon cancer after these examinations was serially 
analyzed for the chromosome aberration rate and MN incidence. The healthy AB-survivor 
was a 65 year old woman who had been exposed to 3Gy to Hiroshima bomb, developed 
colon cancer in 1997. She had been serially observed chromosome aberration rates in 
lymphocytes for 22 years from 1975 to 1997(Fig.2). Translocation was detected by G-banding 
using trypsin solution. The frequency of translocation changed from 22-35% during this 
period, and then increased rapidly to 46 % at the time of colon cancer development. The 
incidences of both spontaneous chromosome aberrations such as chromatid breaks and 
hyperploidy and MN were higher than in the control. Chromatid-type aberrations such as 
breaks and gaps were also serially followed up during this period. Spontaneous 
chromosome aberrations, including the total rates of chromatid-type aberrations and 
hyperdipolidy and hyperploidy, are shown in Fig.2. The frequency of spontaneous 
chromosome aberrations remained at around 6-14% in 1975-1991 and it increased at the time 
of cancer development. MN incidence in lymphocytes was also followed up serially during 
this period and showed a similar pattern (Fig.2). The incidence of MN per 1,000 
lymphocytes was 4-7 and increased to 16 at the time of cancer development. Serial 
observations in an AB-survivors showed that all of the cytogenetic markers of chromosomal 
instability, including translocations, spontaneous chromosome aberrations and MN 
increased at the time of colon cancer development.  
6. Plausible mechanisms for development of chromosome instability in AB-
related leukemia and healthy AB survivors 
In vitro culture studies have demonstrated radiation-induced chromosome instability in 
human and rodent cells after several cell divisions (Kadhim et al., 1992; Holmberg et al. 
1993). These chromosome abnormalities are known as delayed chromosome aberrations 
(Tanaka and Ihda 2008; Tanaka et al. 2008). MN and chromatid-type aberrations are suitable 
cytogenetic markers for detecting chromosome instability because they are eliminated by 
cell division and appear only for a short time after radiation exposure, being associated 
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Fig. 2. Serial observation of MN incidence and chromosome aberration rates in an AB 
survivor who developed colon cancer 
with the approximately 3-year life span of lymphocytes. Chromosome aberrations appear a 
long time after radiation exposure,and are considered to be an indirect radiation exposure. 
The frequency of translocations found in AB-survivors depends on the radiation exposure 
dose, but such aberrations are not suitable for proving chromosomal instability. AB-
survivors who were exposed to higher radiation doses had a higher number of MN in both 
erythroblasts and lymphocytes 30-40 years after the bombing. The incidence of MN in 
lymphocytes clearly increased in a dose- dependent manner. However, conflicting result has 
been reported for dicentric chromosomes in peripheral lymphocytes in healthy AB survivors 
(Hamasaki et al. 2009). These results provide clues as to why the individuals who were 
exposed to radiation showed higher chromosomal instability.  
First, it can be hypothesized that a small percentage of DNA damages is not repaired 
completely and persists for a long time after exposure to radiation. At several days after 
exposure, un-repaired sites are recognized by DNA-binding proteins in an error-prone 
manner. The key issue in this model is the type of mechanism responsible for long-term 
preservation of cells with un-repaired DNAs (Suzuki et al., 2003). Gene recombination 
associated with chromosomal instability will occur at the time. A second hypothesis is that 
inflammation occurs in the organs of AB-survivors exposed to higher radiation 
doses(Neriishi et al., 2003). Macrophages, NK-cells, lymphocytes, monocytes release active 
oxygen species into areas of inflammation. Such oxygen stress can induce chromatid-type of 
aberrations and MN in lymphocytes located in the vicinity.  Similar findings were observed 
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in mice experiments (Lorimore et al., 2001). Interestingly, the most common abnormality for 
delayed chromosome instability observed in mice were chromatid-type aberrations (Watson 
et al. 1996, 2001; Ullrich and Davis 1999), which imply released reactive oxygen species or 
secreted factors related to the chromosome instability. The present serial analyses of MN 
and spontaneous chromosome aberrations in a patient with AB-related colon cancer also 
revealed that chromosome instabilities increased rapidly at the time of cancer development. 
In this case also, it is considered that phagocytic cells that had accumulated in cancer-prone 
tissues released active oxygen species, which induced chromosome aberrations and MN in 
lymphocytes. Of course,however, the first hypothesis also still remains to be examined.  
AB-related leukemias showed more complex chromosome aberrations than de novo 
leukemias. Twenty-seven of the 33 patients with AB-relatedAML showed complex 
chromosome aberrations involving more than three chromosomes including chromosomes 
11 and 20, and the number of chromosomes per cell in AB-relatedleukemias was 3.69, 
compared with 0.93 of de novo leukemia. Only one of the 33 patients (3.1%) had a normal 
karyotype, compared with 44.1% of de novo leukemia. It is considered that phagocytic cells 
that had accumulated in cancer-prone tissues released active oxygen species, in turn 
inducing chromosome aberrations in bone marrow leukemic cells. Of course, the hypothesis 
that malignant clones might have developed from hematopoietic stem cell with higher 
chromosomal instability remains to be investigated. 
7. Different mechanisms for development of AB-related AML and de novo 
AML 
Most of the 33 patients with AB-related AML had a preceding long term MDS stage. 
Therefore, no leukemia type-specific translocations of such as t(8;21), t(15;17), t(11;A)(q23;A) 
and inv(16) were found in these 33 patients. The best approach is to compare types of 
chromosome aberrations between the patients with AB-related MDS and those with AB-
related AML developed from MDS. Translocations on chromosome 11 at 11q13 to 11q23, 
and deletion/loss of chromosome 20 were frequently found in AB-related leukemias (Table 
1). The fact that AB-related leukemias did not have chromosomal breakpoints in the MLL 
gene indicates that AB-related leukemia develops from MDS. MDS has shown to have a 
chromosome breakpoint at 11q22, not 11q23 (Tanaka et al., 2001). Most cases of 11q23 AML 
do not have a MDS stage (Tanaka et al. 2001). The reason why AB-related leukemia did not 
have a translocation breakpoint within the AML1 gene on 21q22 would be the same as that 
for11q22 abnormality in MDS. It is well known that deregulation of the AML1 gene results 
from gene mutations as well as chromosomal translocations such as t(8;21), t(3;21), t(12;21) 
and so on (Harada et al. 2003). 
It has been reported that secondary MDS developing after chemotherapy has been shown to 
have a high incidence of AML1 gene mutation and that MDS shows a higher incidence of 
mutations in the AML1 gene (Harada et al., 2003),in which the frequencies of AML1 point 
mutations were 17% (15/88 cases) in sporadic MDS/AML and 50% (11/22 cases) in secondary 
MDS/AML (4/20). In present study, 2 of 6 patients with AB-related AML had point mutations 
in exon 3 on the AML1 gene. On the other hand, PCR-SSCP analysis of non-AB-related AML 
patients has shown that only 2 showed transformation from MDS and that none of 14 MDS 
patients diagnosed as having RAEB-T had abnormalities( i.e. 2 of 30 non-AB-related AML 
patients showed transformation)( Harada and Harada, 2009), thus indicating that AB-related 
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AML might have a higher incidence of AML1 gene mutation. AMLs that developed in 
residents at living near the Nevada nuclear weapons testing site were reported to have 
chromosome aberrations involving the AML1 gene at 21q22 on chromosome 21 (Hromas et al., 
2000). The two of the present 6 patients with AB-related AML who had been exposed to more 
than 1Gy had point mutations in exon 3, which encodes the RUNT domain of AML1(CBF┚ 2) 
protein. It will be necessary to compare the break points in the AML1 gene (exons 1 and 3) and 
the base changes in the DNA sequences between these two AB-related leukemias and the 
published DNA sequences in MDS. AML 1(CBF┚ 2) protein having point mutation could not 
bind with both histon deacetylation (HDAC) and histon acetylation HAT, which results in 
suppression of transcription and transformation of MDS to AML (Ding et al., 2009). C- terminal 
AML1 point mutations (exons 3-5)  were exclusively found in sporadic MDS/AML, while N-
terminal(exons 6-8) mutations were found in chemotherapy related-secondary MDS/AML 
(Harada et al., 2003). Therefore the role of exon 3 mutations of AML1 gene in the pathogenesis 
of radiation-induced leukemia has been questioned. 
These results suggest that AB-related leukemia is derived from abnormal pluripotent 
hematopoietic stem cells, which are preserved for a long term and show higher genetic 
instability such as microsatellite instability (Nakanishi et al., 2001)(Fig.3), whereas de novo 
AML develops from committed hematopoietic stem cells and shows simple chromosome 
aberrations. t(8;21)-positive leukemic cells arise from committed stem cells, on the other 
hand del(20), t(11,?) might be derived from pluripotent stem cells, as in the case for deletion 
of chromosome 5/monosomy 5 at the pluripotent stem cell level (Nilson et al., 2007). Both of 
these leukemias developed from MDS. Thus the AML1 gene might be activated only at the 
hematopoietic stem cell level. 
Genetic instability is preserved in hematopoietic stem cells damaged by radiation. 
As most AB-leukemias developed from MDS,it is more appropriate to compare AB-
leukemia with de novo AML having a MDS stage before development. Observation of AB-
leukemias in bone marrow smears showed that their hematological features were similar to 
those of MDS found in aged patients. Recent leukemia study showed that a higher incidence 
of MDS was observed in Nagasaki AB survivors (Iwanaga et al., 2011), which implicates that 
AB-related MDS would have more chance to acquire a higher chromosome instability in 
long-term after exposure to AB-radiation. This also suggested that AB-radiation might 
induce earlier development of MDS. Chromosome aberrations found in AB-related 
leukemia included a higher frequency of del(20) and 11q22-11q23 abnormalities than those 
in de novo leukemias. Monosomy and deletion of chromosome 5 (-5/del(5)) occurred at 
almost the same frequencyas those in de novo leukemias. On the other hand monosomy 7 
and deletion of chromosome 7(-7/del(7)) occurred at lower frequencies in AB-related 
leukemia than in de novo leukemias (Arif et al., 1997). This indicated that the type of 
chromosome aberrations in AB-related leukemias showed different from those in de novo 
AML and MDS. AB radiation might induce different type of cancer as well as cancer 
development with a shorter latency. A similar finding has been observed using analyses of 
array CGH and cell surface marker by FACS sorting for low-dose-rate radiation-induced 
murine leukemias, lymphomas and tumors by The Institute for Environmental  Science 
(Tanaka et al., 2007; Hirouchi et al., 2009, 2011).  
In conclusion, chromosome and oncogene features revealed in present study might be 
related to the higher incidence of AML transformed from MDS in AB survivors a long time 
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Fig. 3. Hypothetical schema of the development of radiation-induced leukemia from 
pluripotent hematopoietic stem cells 
after exposure, and these findings are important for understanding the mechanisms 
responsible for radiation-induced leukemia. 
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